The Velocity Constraint: How a Fast-Enrolling Pivotal Forced Pulse Biosciences to Rewrite Its Own Protocol
nsPFA catheter crosses its study midpoint in ~2 months, so PLSE widens AAD eligibility, adds 19 patients, and converts in-lab speed into a hospital-economics pitch
PLSE · Earnings Call · 2026-08-06
The protocol can't keep up
Pulse Biosciences entered Q2 2026 with a promise and ended it with a constraint. The NANOPULSE-AF pivotal IDE, which began enrolling in April, crossed its 82-patient midpoint in barely two months, and management now confirms completion lands in early October — three months ahead of the original schedule. That enrollment velocity quickly became a *management* problem: FDA site caps, the blended 6/12-month endpoint, and the question of what to do with a study that fills faster than the follow-up clock. The study protocol amendment is the tell. Management widened eligibility so a patient can qualify after failing any one of four AAD classes (the two calcium-channel classes were added), and popped the target from 145 to 164 patients to rebalance statistics against a slightly different real-world phenotype. As LaViolette put it, “we felt it was important to add the other 2 AAD classes so that they could fail any 1 of the classes.” — Paul LaViolette, CEO · 2026-08-06 The 19 extra patients are effectively free because the real world waiting time to completion barely moves.The in-lab experience is the pitch
What's genuinely new this quarter is that the Physicians' lab experience is being translated into a repeatable hospital-economics argument — not just an efficacy one. In prepared remarks, LaViolette set the contrast bluntly: “We have seen multiple sites perform 5 and up to 7 cases in a day... With other ablation catheters currently available, EP labs generally do not schedule more than 2 to 3 cases per day.” — Paul LaViolette, CEO · 2026-08-06 That acute experience — five-second lesions, a minimal ablation set, a "straightforward learning curve" — is now doing double duty as the adoption story and the ROI story, with Bob Duggan making the economics explicit:It's the same throughline as the prior quarter's call, where LaViolette framed the differentiator as physician embrace of the technology because "it represents an improvement in workflow, in speed and ease of use" (“physician interest in the technology because they believe it will treat their patients well and importantly, because it represents an improvement in workflow, in speed and ease of use” — Paul LaViolette, CEO · 2026-02-20). The difference is that the anecdote now has confirmed numbers behind it.The quantity of patients treated is a very positive product economic feature for the OR. It is OR ROI that is significant.
The long pole, and a quieter business underneath
With enrollment this fast, the blended 6/12-month primary endpoint's long pole is the first cohort's 12-month data — LaViolette's answer to Bill Plovanic's question:adding that all timeline-management levers (enrollment pacing, follow-up, clean submission) are in play. Two prior-quarter themes are holding: the study runs entirely on EnSite, consistent with the Q1 statement that “EnSite will be the most common, predominant and likely the only system used in our IDE,” — Paul LaViolette, CEO and Co-Chairman · 2026-05-07 and the ambulatory-surgery ambition — "conscious sedation is a likely viable sedation protocol... as we enter the U.S. market and migrate patient therapies to the ambulatory surgery setting" (“.” — Paul LaViolette, CEO and Co-Chairman · 2026-05-07) — was re-lit as "chapter 2" of commercialization. The surgical clamp and thyroid programs run second fiddle — 70+ EU clamp patients at 94% PVI durability, Vybrance's $434k of disposables plus the Clayman Thyroid Center partnership and a fully enrolled PRECISE-BTN — but the keyword history tells you where the air is: the biggest keyword decliner year-over-year is *cardiac clamp* while gainers are *enrolling*, *raised*, and *Hospital*.12 months from the earlier patient group is the long pole in the tent,